EFL

Cohort Year: 2023-2024

Tracks: Life Sciences

VISIT WEBSITE

GlyTherix

GlyTherix is a clinical-stage targeted radiotherapy company developing a first-in-class therapeutic antibody to treat solid tumors expressing Glypican-1 (GPC-1), a cell surface target that occurs within many solid tumors including prostate, bladder & pancreatic cancers.